Trials / Unknown
UnknownNCT03920813
Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy
Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
The present study was conducted to assess the population pharmacokinetics of 6-mercaptopurine (6-MP) in Pediatric Acute Lymphoblastic Leukemia (ALL) and genetic polymorphisms
Detailed description
The investigators' purpose was to identify genetic factors and metabolite concentrations associated with both hematological toxicity in patients with ALL maintained on 6-MP in Chinese.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mercaptopurine | Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L. |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2019-04-19
- Last updated
- 2019-04-23
Source: ClinicalTrials.gov record NCT03920813. Inclusion in this directory is not an endorsement.